Quick Search  in all journalsin this journalin this issue Journals Home Drugs of the Future Issues Drugs of the Future Policies & Guidelines Permissions My Profile Contact Us Shopping Cart Purchase History

	Drugs of the Future		Register or sign in
	Drugs Fut 2008, 33(1): 49 ISSN 0377-8282 e-ISSN 2013-0368 Copyright 2008 Clarivate CCC: 0377-8282 DOI: 10.1358/dof.2008.033.01.1158296
	IL-12/IL-23 inhibitors: A promising approach to the treatment of inflammatory disorders Wada, Y.
	Recent clinical trials with anti-interleukin (IL)-12p40 antibodies in psoriasis and Crohn's disease patients have demonstrated the therapeutic efficacy of this approach and have validated IL-12/IL-23 as an attractive target for the development of effective new drugs for the treatment of autoimmune and inflammatory disorders. IL-23, a new member of the IL-12 family, shares the p40 subunit with IL-12, and is similarly inhibited by anti-IL-12p40 antibodies. Emerging data clearly indicate that IL-23 is essential for the expansion and survival of Th17 T-cells, which have been identified as responsible for many of the inflammatory autoimmune responses. Investigation of the regulation of the p40 and the IL-23-specific p19 subunits led to the finding of a selective and dominant role for c-Rel in activating their promoters. This review describes drugs reported to inhibit the production of IL-12/IL-23, recent studies on their mechanisms of action in modulating the expression of these cytokines, and their potency and selectivity. Full Text: HTML, PDF

	© Clarivate. All rights reserved.
	Copyright Notice	Terms of Use	Privacy Statement	Cookie Policy	Manage cookie preferences